MX2009008914A - Anticuerpos y composiciones farmaceuticas que contienen los mismos, utiles para inhibir la actividad de metaloproteinas. - Google Patents

Anticuerpos y composiciones farmaceuticas que contienen los mismos, utiles para inhibir la actividad de metaloproteinas.

Info

Publication number
MX2009008914A
MX2009008914A MX2009008914A MX2009008914A MX2009008914A MX 2009008914 A MX2009008914 A MX 2009008914A MX 2009008914 A MX2009008914 A MX 2009008914A MX 2009008914 A MX2009008914 A MX 2009008914A MX 2009008914 A MX2009008914 A MX 2009008914A
Authority
MX
Mexico
Prior art keywords
metalloproteins
antibodies
pharmaceutical compositions
compositions containing
inhibiting activity
Prior art date
Application number
MX2009008914A
Other languages
English (en)
Spanish (es)
Inventor
Irit Sagi
Tamar Danon
Netta Sela
Abraham Shanzer
Rina Arad-Yellin
Raghavendra Kikkeri
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of MX2009008914A publication Critical patent/MX2009008914A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/06—Zinc compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2009008914A 2007-02-23 2008-02-21 Anticuerpos y composiciones farmaceuticas que contienen los mismos, utiles para inhibir la actividad de metaloproteinas. MX2009008914A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90285407P 2007-02-23 2007-02-23
PCT/IL2008/000230 WO2008102359A1 (en) 2007-02-23 2008-02-21 Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins

Publications (1)

Publication Number Publication Date
MX2009008914A true MX2009008914A (es) 2009-08-28

Family

ID=39534848

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008914A MX2009008914A (es) 2007-02-23 2008-02-21 Anticuerpos y composiciones farmaceuticas que contienen los mismos, utiles para inhibir la actividad de metaloproteinas.

Country Status (11)

Country Link
US (5) US8324355B2 (enExample)
EP (1) EP2155691B1 (enExample)
JP (2) JP5513130B2 (enExample)
KR (1) KR20090113908A (enExample)
CN (1) CN101702906B (enExample)
BR (1) BRPI0807256A2 (enExample)
CA (1) CA2678304A1 (enExample)
IL (2) IL224120A (enExample)
MX (1) MX2009008914A (enExample)
RU (1) RU2503682C2 (enExample)
WO (1) WO2008102359A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2155691B1 (en) 2007-02-23 2016-01-13 Yeda Research and Development Co. Ltd. Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
CA2707637A1 (en) 2007-12-17 2009-06-25 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins
US8013125B2 (en) * 2008-03-03 2011-09-06 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
EP4032538A3 (en) * 2009-03-02 2022-10-26 Massachusetts Institute of Technology Methods and products for in vivo enzyme profiling
CN102822202B (zh) 2010-01-27 2015-07-22 耶达研究及发展有限公司 抑制金属蛋白的抗体
WO2012027721A2 (en) 2010-08-27 2012-03-01 Gilead Biologics, Inc Antibodies to matrix metalloproteinase 9
CN103370337B (zh) * 2010-10-28 2015-12-09 耶达研究及发展有限公司 用于产生针对金属酶的抗体的方法
US10314909B2 (en) 2011-10-21 2019-06-11 Dyax Corp. Combination therapy comprising an MMP-14 binding protein
MD20140108A2 (ro) 2012-02-29 2015-03-31 Gilead Biologics, Inc. Anticorpi împotriva metaloproteinazei 9 matriciale
JP6847660B2 (ja) 2013-06-07 2021-03-24 マサチューセッツ インスティテュート オブ テクノロジー リガンドをコードする合成バイオマーカーのアフィニティベースの検出
TWI750108B (zh) 2014-04-03 2021-12-21 瑞士商Ｃｓｌ貝林股份有限公司 免疫球蛋白之霧化
US11019620B2 (en) 2014-05-19 2021-05-25 Qualcomm Incorporated Apparatus and method for inter-band pairing of carriers for time division duplex transmit- and receive-switching and its application to multiplexing of different transmission time intervals
US11432305B2 (en) * 2014-05-19 2022-08-30 Qualcomm Incorporated Apparatus and method for synchronous multiplexing and multiple access for different latency targets utilizing thin control
EP2985296A1 (en) * 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
EP3424168B1 (en) * 2016-04-04 2022-06-01 Samsung Electronics Co., Ltd. Method and apparatus for transmitting and receiving feedback in wireless communication system
WO2018148595A1 (en) * 2017-02-10 2018-08-16 Washington University Antibodies to tip1 and methods of use thereof
AU2018248327B2 (en) 2017-04-07 2024-10-10 Massachusetts Institute Of Technology Methods to spatially profile protease activity in tissue and sections
KR102657653B1 (ko) 2017-07-18 2024-04-16 다이이찌 산쿄 가부시키가이샤 활성형 mmp-9 결합 펩티드
EP3856921B1 (en) 2018-09-25 2026-04-29 Massachusetts Institute Of Technology Lung protease nanosensors and uses thereof
EP3911753A1 (en) 2019-01-17 2021-11-24 Massachusetts Institute of Technology Sensors for detecting and imaging of cancer metastasis
IL264768A (en) * 2019-02-10 2020-08-31 Sagi Irit Anti-matrix metalloproteinase 7 (mmp-7) inhibitory antibody and uses thereof
US11332546B2 (en) 2019-05-21 2022-05-17 The Regents Of The University Of California Protease inhibitory antibodies and methods of use thereof
JP2024514533A (ja) * 2021-04-05 2024-04-02 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 神経伝達に対する鏡像異性体選択的作用
WO2025075789A1 (en) * 2023-10-03 2025-04-10 Merck Sharp & Dohme Llc Immunoassay for detecting tau phosphorylated at serine 413
EP4788430A1 (en) 2023-10-05 2026-08-12 Ashibio, Inc. Methods and compositions for treating mmp-9 mediated disorders
WO2026076260A1 (en) 2024-10-03 2026-04-09 Ashibio, Inc. Methods and compositions for mmp-9 inhibition for use with non-genetic heterotopic ossification disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595700A (en) 1984-12-21 1986-06-17 G. D. Searle & Co. Thiol based collagenase inhibitors
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5525629A (en) 1992-04-07 1996-06-11 British Bio-Technology Limited Inhibition of cytokine production
GB9320660D0 (en) 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
WO1995029689A1 (en) 1994-04-28 1995-11-09 Merck & Co., Inc. N-carboxyalkyl derivatives as antidegenerative active agents
WO1995029892A1 (en) 1994-04-28 1995-11-09 The Du Pont Merck Pharmaceutical Company Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents
GB9416897D0 (en) 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
ES2185750T3 (es) 1995-08-08 2003-05-01 Ono Pharmaceutical Co Derivados de acido hidroxamico utiles para la inhibicion gelatinasa.
IL116126A0 (en) * 1995-11-24 1996-01-31 Yeda Res & Dev Process for the preparation of bacteriochlorophyllis some novel compounds of this type and pharmaceutical compositions comprising them
DK0780386T3 (da) 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
WO1997024117A1 (en) 1996-01-02 1997-07-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds
EP0994104A4 (en) 1996-06-27 2001-09-12 Ono Pharmaceutical Co ARYL SULFIDE, SULFOXIDE AND SULPHONE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING THEM AS AN ACTIVE INGREDIENT
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
OA11589A (en) 1998-07-30 2004-07-30 Warner Lambert Co Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases.
IL178921A0 (en) * 1998-12-24 2007-03-08 Yeda Res & Dev Caspase-8 interacting proteins
ATE517926T1 (de) * 2003-04-04 2011-08-15 Yeda Res & Dev Antikörper zur hemmung der aktivität von mmp-2 und mmp-9
EP2155691B1 (en) 2007-02-23 2016-01-13 Yeda Research and Development Co. Ltd. Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
CN102822202B (zh) 2010-01-27 2015-07-22 耶达研究及发展有限公司 抑制金属蛋白的抗体

Also Published As

Publication number Publication date
US20180134808A1 (en) 2018-05-17
EP2155691A1 (en) 2010-02-24
US20100233188A1 (en) 2010-09-16
IL224120A (en) 2016-05-31
KR20090113908A (ko) 2009-11-02
IL224121A (en) 2016-05-31
JP2013241435A (ja) 2013-12-05
JP5792231B2 (ja) 2015-10-07
JP5513130B2 (ja) 2014-06-04
BRPI0807256A2 (pt) 2014-07-22
US20130030158A1 (en) 2013-01-31
CN101702906A (zh) 2010-05-05
AU2008218525A1 (en) 2008-08-28
US8486653B2 (en) 2013-07-16
US9416195B2 (en) 2016-08-16
US20130224225A1 (en) 2013-08-29
RU2503682C2 (ru) 2014-01-10
WO2008102359A9 (en) 2009-05-22
US9902783B2 (en) 2018-02-27
RU2009132006A (ru) 2011-02-27
US20160257765A1 (en) 2016-09-08
WO2008102359A1 (en) 2008-08-28
EP2155691B1 (en) 2016-01-13
CA2678304A1 (en) 2008-08-28
CN101702906B (zh) 2014-02-12
JP2010519289A (ja) 2010-06-03
US8324355B2 (en) 2012-12-04

Similar Documents

Publication Publication Date Title
BRPI0513990A (pt) composições de silano, processos para suas preparações e composições de borracha contendo as mesmas
NO20091706L (no) Inhibitorer av hepatitt C virus
ATE296797T1 (de) N-(aryl/heteroaryl/alkylacetyl) amino saüre amide,pharmazeutische zusammensetzungen damit, und methodenzur inhibierung beta-amyloid peptid freisetzung oder synthese
IL190333A (en) Process and intermediates for the synthesis of caspofungin
ATE427932T1 (de) 11beta-hsd1-inhibitoren
NO20084701L (no) Ny heterocyklisk forbindelse eller salt eller intermediat derav
EA201171328A1 (ru) Производное замещенного изохинолина
IL189466A0 (en) Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
HUP0002395A2 (hu) Csípőbél epesav transzportot gátló hatású benzotiepineket és HMG Co-A reduktáz gátlókat tartalmazó kombinált gyógyszerkészítmények
NO20091704L (no) Inhibitorer av hepatitt C virus
JO2644B1 (en) Derivatives of N- (amino-aryl mixture) -H1- indole-2-carboxamide Synthesis and therapeutic use
NO20091707L (no) Inhibitorer av hepatitt C virus
NO20074310L (no) Spiroketalderivat og anvendelse derav som diabetesmedisin
MY149180A (en) Uracil compound having inhibitor activity on human deoxyuridine triphosphatase or salt thereof
RU2009132006A (ru) Антитела и содержащие их фармацевтические композиции, подходящие для ингибирования активности металлопротеинов
ATE503746T1 (de) Neue imidazolidinderivate
WO2006060424A3 (en) Inducible nitric oxide synthase dimerization inhibitors
EP1961734A4 (en) AMINE CONNECTION AND ITS USE FOR MEDICAL PURPOSES
ES2199696A1 (es) Mezclas de estabilizantes
DE602004003948D1 (de) Herstellung von 2-18f-2-desoxy-d-glucose durch festphasensynthese
EA200702375A1 (ru) Производные мочевины, способы их получения и применения
WO2006103101A3 (en) MEANS FOR THE INHIBITION OF ANTI-β1-ADRENERGIC RECEPTOR ANTIBODIES
WO2004103967A3 (en) Thiocarbamate inhibitors of alpha-4 integrins
EP2036896A4 (en) CYCLIC AMINE COMPOUND
SG146692A1 (en) Melanin concentrating hormone antagonists

Legal Events

Date Code Title Description
FA Abandonment or withdrawal